Doctors 2.0 & You to address the "explosion of digital health tools" with new subjects, speakers, partners

5 - 6 June 2014, Paris, France.
Doctors 2.0 & You, partner of Stanford Medicine X and known for its 360° inclusive perspective on the patient, the physician, and digital tools, today announced 4th edition highlights. Remarking that "healthcare is now a recognized part of the explosion in social media, apps, quantified self and wearables," founder Denise Silber, confirms that "the June, 2014 program will provide an intensive look at the many moving parts of digital health and their results to date. How do patients and physicians benefit?"

Doctors 2.0 & You will bring attendees the latest insights and research on the ePatient and the digital doctor, individually and in communities, social media campaigns, eReputation, mobile apps, Serious Games and simulation, Quantified self and wearables including Google Glass and sensors. These tools will be envisaged from the standpoint of patients and physicians and other key stakeholders: pharma and device industries and suppliers, technology companies, payers, government. Participants originate from around the world and provide both a global and national perspective.

"So many people keep talking about digital, 2.0, social media... applied to the healthcare world. Doctors 2.0 & You helps make it happen, by spotting trends and talent and bringing la crème de la crème together. Doctors 2.0 & You is a best practice in Europe,” said Bernard Peyrical, Sanofi.

Some highlights from the 20 hours of activities including 22 parallel sessions and plenary, and 6 hours of Networking

  • Connected Objects, Quantified Self: Special activities around connected objects and quantified self will be developed for attendees thanks to the new Platinum Partnership with iHealthLabs Europe, founded by Uwe Diegel. Other quantified self players, ePatient and physician users, and pharma (Novartis) will provide their testimonials.
  • Google Glass: Four international pioneer Google Glass explorers will present exciting perspectives on health and medicine. Diversifying digital pharma
  • Pharma partners from hospitals and patient and physician communities will discuss relationships and results.
  • Dr Berci Mesko, founder of Webicina and medical futurist, will provide a limited seat Master Class on quality of web resources.
  • Award winning mobile apps and social media campaigns from Europe and the US will explain how they did it.
  • Three authors from the US, Hungary, and France will sign their books at the June 5th networking reception.
  • Stanford Medicine X and Doctors 2.0 & You will sponsor a medical student leader participant.
  • Announcement of the Doctors 2.0 & You Start Up Finalist who will fly to Palo Alto in September to present
  • Returning partners Novartis, Sanofi, LexisNexis and DocCheck will provide exciting activities in the exhibit hall.
  • Doctors 2.0 & You welcomes new supporting partners Ben's Friends and SOPE (Society of Physician Entrepreneurs).

For further information, please visit:
http://www.doctors20.com

About Doctors 2.0 & You
The Doctors 2.0TM & You conference series, organized by Basil Strategies, digital health consultancy (Paris), is the only international congress devoted to the understanding of how physicians use New Technologies, Web 2.0 tools and Social Media to communicate with colleagues, patients, payers, pharmaceutical companies and public agencies. The 4th edition will take place in Paris on June 5-6, 2014. The conference website and blog includes videos, past presentations, interviews, and other content.

Most Popular Now

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

A soybean protein blocks LDL cholesterol productio…

A protein in soybeans blocks the production of a liver enzyme involved in the metabolism of triglycerides and low-density lipoprotein, scientists found in a recent study...

Discovery of anti-cancer chemistry makes skullcap …

The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chin...